Asset Details
Do you wish to reserve the book?
Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT
Do you wish to request the book?
Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT
2022
Overview
Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PK) and metabolism of citrate in liver failure patients who require CRRT with regional citrate anticoagulation (RCA). This prospective clinical PK study was conducted at King Chulalongkorn Memorial Hospital between July 2019 to April 2021, evaluating seven acute liver failure (ALF) and seven acute-on-chronic liver failure (ACLF) patients who received CRRT support utilizing RCA as an anticoagulant at a citrate dose of 3 mmol/L. For evaluation of the citrate PK, we delivered citrate for 120 min and then stopped for a further 120 min. Total body clearance of citrate was 152.5 ± 50.9 and 195.6 ± 174.3 mL/min in ALF and ACLF, respectively. The ionized calcium, ionized magnesium, and pH slightly decreased after starting citrate infusion and gradually increased to baseline after stopping citrate infusion. Two of the ACLF patients displayed citrate toxicity during citrate infusion, while, no ALF patient had citrate toxicity. In summary, citrate clearance was significantly decreased in critically ill ALF and ACLF patients receiving CRRT. Citrate use as an anticoagulation in these patients is of concern for the risk of citrate toxicity.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Acute-On-Chronic Liver Failure - blood
/ Acute-On-Chronic Liver Failure - diagnosis
/ Acute-On-Chronic Liver Failure - physiopathology
/ Acute-On-Chronic Liver Failure - therapy
/ Adult
/ Aged
/ Anticoagulants - administration & dosage
/ Anticoagulants - adverse effects
/ Anticoagulants - pharmacokinetics
/ Citric Acid - administration & dosage
/ Citric Acid - adverse effects
/ Citric Acid - pharmacokinetics
/ Continuous Renal Replacement Therapy - adverse effects
/ Female
/ Humanities and Social Sciences
/ Humans
/ Kidney Diseases - physiopathology
/ Liver
/ Liver Failure, Acute - blood
/ Liver Failure, Acute - diagnosis
/ Liver Failure, Acute - physiopathology
/ Liver Failure, Acute - therapy
/ Male
/ Patients
/ Science
/ Toxicity
